Annexon surges 48% after scheduling update for Guillain-Barré Syndrome drug data. Last Updated: June 3, 2024 at 8:10 p.m. ET First Published: June 3, 2024 at 6:44 p.m. ET. Share.

The Food and Drug Administration has flagged Guillain-Barre syndrome, a rare neurological condition, as a potential risk for Pfizer’s respiratory syncytial virus (RSV) vaccine. Two people in … ...

Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Guillain-Barre Syndrome (GBS) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering. This comprehensive analysis of ...

Annexon announces positive topline results from pivotal phase 3 trial for first-in-class C1q blocking antibody ANX005 in Guillain-Barré syndrome. News release. Annexon, Inc. June 4, 2024.

The Food and Drug Administration (FDA) has granted Fast Track designation to ANX005 (Annexon Biosciences) for the treatment of Guillain-Barré Syndrome (GBS), an autoimmune disease that can lead ...

(RTTNews) - Annexon, Inc. (ANNX) announced the European Medicines Agency granted orphan drug designation to ANX005 for the treatment of Guillain-Barré Syndrome. Advantages of the orphan drug ...

Johnson & Johnson’s beleaguered Covid-19 vaccine may be associated with a small increased risk of Guillain-Barré syndrome, a rare but potentially serious neurological condition, federal ...

In extremely rare cases, Guillain-Barré Syndrome can occur after a vaccination, the Centers for Disease Control says, and there was some initial concern from Americans that the COVID-19 vaccines ...

Annexon surges 48% after scheduling update for Guillain-Barré Syndrome drug data Provided by Dow Jones Jun 4, 2024, 12:10:00 AM. By Josh Beckerman .